2017/10/09
SHANGHAI, Oct. 9, 2017 -- WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, today announced that it has been awarded the 2017 Frost & Sullivan Global Integrated Drug R&D Services Competitive Strategy Innovation & Leadership Award.
Read more2017/07/31
Shanghai, July 31, 2017: STA Pharmaceutical Co., Ltd. (STA) – a WuXi AppTec company and the leading open-access capability and technology platform for small molecule pharmaceutical development and manufacturing – announces that it has merged with WuXi AppTec’s Pharmaceutical Development Services (PDS) division.
Read more2017/07/24
SHANGHAI, July 24, 2017 --STA Pharmaceutical Co., Ltd. (STA) – a WuXi AppTec subsidiary and the leading open-access capability and technology platform for small molecule pharmaceutical development and manufacturing – announces it signed a supply agreement with the oncology-focused biopharmaceutical company, TESARO, Inc. (TESARO) for certain starting and intermediate materials for ZEJULA™ (niraparib).
Read more2017/05/15
SHANGHAI, May 15, 2017 -- WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, today announced that it has completed its acquisition of HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO).
Read more2017/03/27
SHANGHAI; BOSTON, Mass., 27 March, 2017 – LabNetwork, WuXi AppTec’s global chemistry ecommerce platform company, today announced a new collaboration with Elsevier, a world-leading provider of scientific, technical and medical information products and services.
Read more